Coverage Initiated by BTIG Research – for Checkmate Pharmaceuticals (NASDAQ:CMPI)

0
47

Stock analysts at BTIG Research – 4 stars initiated coverage on shares of  Checkmate Pharmaceuticals (NASDAQ:CMPI) in a report issued on Friday. The brokerage set a Buy rating on the Medical stock. A price-to-earnings ratio of #N/A and a beta of #N/A. Checkmate Pharmaceuticals has a twelve month low $3.63 of  and a twelve month high of $23.10.

Shares of Checkmate Pharmaceuticals traded no change $0.00 on Friday, reaching $4.10. 104 shares of the stock traded hands, compared to its average volume of 40793. Shares of Checkmate Pharmaceuticals were trading at $4.10 on Friday. The firm’s 50 day moving average is $$4.81 and its 200 day moving average is $8.50.Checkmate Pharmaceuticals  has a 12 month low of $4.01 and a 12 month high of $23.10. While on yearly highs and lows, Checkmate Pharmaceuticals’s today has traded high as $4.52 and has touched $4.01 on the downward trend. See More Analyst Rating at: RATING

Checkmate Pharmaceuticals Earnings and What to expect: 

Checkmate Pharmaceuticals last posted its earnings data on August 12th, 2021. The reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.14. Checkmate Pharmaceuticals has generated ($4.49) earnings per share over the last year. Earnings for Checkmate Pharmaceuticals are expected to grow in the coming year, from ($2.95) to ($2.64) per share. Checkmate Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, November 12th, 2021 based off prior year’s report dates.

Earnings for Checkmate Pharmaceuticals are expected to grow in the coming year, from ($2.95) to ($2.64) per share. The P/E ratio of Checkmate Pharmaceuticals is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Checkmate Pharmaceuticals is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Checkmate Pharmaceuticals has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Checkmate Pharmaceuticals (NASDAQ:CMPI) Moving Average Technical Analysis

5 day Moving Average is $4.05 And 5 day price change is $0.09 (2.24%)  with average volume for 5 day average is 64,740. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $4.10 and 20 day price change is -$0.77 (-15.81%) and average 20 day moving volume is 48,190. 50 day moving average is $4.81  and 50 day price change is -$1.16 ( -22.05%)  and with average volume for 50 days is : 33,044. 200 day moving average is $8.50  and 200 day price change is -$10.95 (-72.76%)  and with average volume for 200 days is : 47,623.

Other owners latest trading in Checkmate Pharmaceuticals :

  • On 8/17/2021 shares held by Millennium Management LLC were 40,422 which equates to market value of $0.24M and appx 0.00% owners of Checkmate Pharmaceuticals
  • On 8/17/2021 shares held by Bridgeway Capital Management LLC were 21,500 which equates to market value of $0.13M and appx 0.00% owners of Checkmate Pharmaceuticals
  • On 8/16/2021 shares held by Bank of America Corp DE were 6,331 which equates to market value of $37K and appx 0.00% owners of Checkmate Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 75.49% for Checkmate Pharmaceuticals

See More Analyst Rating at: RATING